About this visual
A November 2026 overview of 12 investigational obesity therapies, spanning amylin-based treatments, GLP-1/GIP pathways, glucagon-containing combinations, and GLP-1 receptor agonists.
Clinicians Evidence infographic
The Next Wave of Obesity Medicine: 12 Investigational Therapies
November 12, 2026 · By Joe Zucchi, PA-C, MPAS
1536 × 2048 px · PDF includes the original image and a link to this page.
Related visuals
Get to Know VK2735
A six-slide overview of VK2735, covering injectable and oral Phase 2 results, exploratory maintenance dosing, dose-specific tolerability and Phase 3 programs.
Clinical Trials & Pipeline
Retatrutide vs Semaglutide 2 mg
A visual summary of sponsor-reported 80-week Phase 3 TRANSCEND-T2D-2 results comparing retatrutide with semaglutide 2 mg in adults with type 2 diabetes.
Clinical Trials & Pipeline
Amylin: The Next Frontier in Obesity Medicine?
Explore amylin biology and clinical trial results for cagrilintide, CagriSema, petrelintide, zenagamtide (amycretin), and eloralintide in obesity medicine.
Clinical Trials & Pipeline
Amylin therapies, triple agonists, and monthly injections: the next wave of obesity medicine is bringing exciting new possibilities.
Here is my latest update of 12 investigational therapies in Phase 3 development or FDA review. There’s a lot to look forward to as we learn where each may fit!
🔹 AMYLIN-BASED
- CagriSema | Novo Nordisk
Combines cagrilintide and semaglutide, targeting amylin and GLP-1 pathways.
- Zenagamtide | Novo Nordisk
Formerly amycretin. A single molecule targeting both amylin and GLP-1 receptors.
- Petrelintide | Zealand Pharma + Roche
A long-acting amylin analogue being developed as a weekly injection.
- Eloralintide | Eli Lilly and Company
A selective amylin receptor agonist, adding another approach beyond incretin-only therapy.
🔹 GLP-1 + GIP PATHWAYS
- VK2735 | Viking Therapeutics, Inc.
A dual GLP-1/GIP agonist. The infographic shows the injectable program; an oral formulation is also being studied.
- Ribupatide | Hengrui Pharma + Kailera Therapeutics
Another dual GLP-1/GIP agonist, with the illustrated result coming from a Phase 3 trial in China.
- Enicepatide | Roche / Genentech
Formerly CT-388, a once-weekly dual GLP-1/GIP agonist.
- MariTide | Amgen
Pairs GLP-1 receptor agonism with GIP receptor antagonism, with less-frequent dosing under study.
🔹 GLUCAGON-CONTAINING
- Retatrutide | Eli Lilly and Company
A triple agonist targeting GLP-1, GIP and glucagon receptors.
- Survodutide | Boehringer Ingelheim + Zealand Pharma
Combines GLP-1 and glucagon receptor agonism.
🔹 GLP-1 RECEPTOR AGONISTS
- Aleniglipron | Structure Therapeutics
An oral, small-molecule GLP-1 receptor agonist.
- Berobenatide | Pfizer
Formerly MET-097i, now PF-08653944. An injectable GLP-1 receptor agonist being studied with monthly dosing.
It is exciting how these options might help us better match treatment to the individual. Weight loss is important, but so are tolerability, durability, health outcomes, dosing preferences and access.
The graphic shows selected mean losses from baseline in adults without type 2 diabetes, mostly efficacy estimands. These are different trials, not head-to-head comparisons. The phases on the cards refer to the source studies, including early, exploratory and interim results, rather than each program’s current stage.
November 2026 update of investigational therapies. Explore my full pipeline tracker featuring 47 investigational obesity medications in Phase 2 and Phase 3 development. Link in the comments.
#ObesityMedicine #ClinicalResearch #ObesityCare #GLP1